Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.43 |
| ▸ | ESR1 | P03372 | 6/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.39 |
| ▸ | CBFB | Q13951 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29534800 | 1.00 | ALOX15 (0.44) | ALOX15CYP3A4CHRM1MAOATBXA2R | |
| SCHEMBL28267893 | 0.82 | ESR2 (0.38) | ALOX15CYP3A4CHRM1MAOATBXA2R | |
| SCHEMBL16295806 | 0.80 | ACHE (0.46) | ALOX15CYP3A4CHRM1MAOATBXA2R | |
| SCHEMBL13084437 | 0.79 | CYP3A4 (0.48) | ALOX15CYP3A4CHRM1MAOATBXA2R | |
| SCHEMBL30381231 | 0.77 | TYR (0.42) | ALOX15CYP3A4ENPP2ALDH1A1LMNA | |
| SCHEMBL29591086 | 0.77 | TDP1 (0.50) | ALOX15CYP3A4ACHEALDH1A1HSD17B10 | |
| SCHEMBL3791591 | 0.77 | TYR (0.42) | ALOX15CYP3A4ENPP2ALDH1A1LMNA | |
| SCHEMBL42414 | 0.77 | TDP1 (0.50) | ALOX15CYP3A4ACHEALDH1A1HSD17B10 | |
| SCHEMBL3928671 | 0.75 | CA2 (0.50) | ENPP2KDM4EALDH1A1TSHR | |
| Ammonia Solution, Strong SCHEMBL28219158 | 0.75 | TDP1 (0.48) | ALOX15CYP3A4ALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| CN-118240200-A | Low-dielectric fluorine-containing polyarylether resin and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2024-06-25 | — | — | CN | claimed |
| CN-116731315-B | Boron-containing phthalonitrile resin and preparation method and application thereof | 中国科学院化学研究所 | 2024-06-21 | — | — | CN | claimed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | claimed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230363426-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-16 | — | — | US | claimed |
| US-11793220-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-10-24 | — | — | US | claimed |
| US-20230210790-A1 | GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES | THE JOHNS HOPKINS UNIVERSTY | 2023-07-06 | — | — | US | claimed |
| EP-4157998-A1 | GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES | The Johns Hopkins University (US) | 2023-04-05 | — | — | EP | claimed |
| US-20220264914-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-08-25 | — | — | US | claimed |
| WO-2022159439-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-20220225647-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| US-20220225646-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| EP-3344232-B1 | MICELLES FOR MUCOADHESIVE DRUG DELIVERY | UNIV MCMASTER (CA) | 2022-01-26 | — | — | EP | claimed |
| US-10611908-B2 | Micelles for mucoadhesive drug delivery | MCMASTER UNIVERSITY (CA) | 2020-04-07 | — | — | US | claimed |
| US-20180265694-A1 | Micelles for Mucoadhesive Drug Delivery | MCMASTER UNIVERSITY (CA) | 2018-09-20 | — | — | US | claimed |
| EP-3344232-A1 | MICELLES FOR MUCOADHESIVE DRUG DELIVERY | Mcmaster University (CA) | 2018-07-11 | — | — | EP | claimed |
| WO-2017035656-A1 | MICELLES FOR MUCOADHESIVE DRUG DELIVERY | MCMASTER UNIVERSITY (CA) | 2017-03-09 | — | — | WO | claimed |
| EP-4565562-B1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LTD (GB) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747244-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | Redx Pharma Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260042745-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LIMITED (GB) | 2026-02-12 | — | — | US | disclosed |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-12402638-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250236621-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-4565562-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | Nxera Pharma UK Limited (GB) | 2025-06-11 | — | — | EP | disclosed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250122173-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LTD (GB) | 2025-04-17 | — | — | US | disclosed |
| US-12240846-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2025-03-04 | — | — | US | disclosed |
| WO-2025043191-A1 | PRC2 INHIBITORS FOR USE IN TREATING SICKLE CELL DISEASE | ORIC PHARMACEUTICALS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-12232516-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| WO-2025017305-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025017306-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2025-01-23 | — | — | WO | disclosed |
| US-12193465-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240398811-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | ORIC PHARMACEUTICALS, INC. | 2024-12-05 | — | — | US | disclosed |
| CN-119019388-A | 5-And 6-azaindole compounds for inhibiting Bcr-Abl tyrosine kinase | 英莱汶公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20240368106-A1 | HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240317713-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2024-09-26 | — | — | US | disclosed |
| EP-4043466-B1 | PRC2 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-08-21 | — | — | EP | disclosed |
| EP-4404932-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | Oric Pharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| EP-4397308-A2 | COMPOUNDS AND THEIR METHODS OFUSE | Praxis Precision Medicines, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118240200-A | Low-dielectric fluorine-containing polyarylether resin and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2024-06-25 | — | — | CN | disclosed |
| CN-116731315-B | Boron-containing phthalonitrile resin and preparation method and application thereof | 中国科学院化学研究所 | 2024-06-21 | — | — | CN | disclosed |
| CN-112543764-B | Amide compound with BET proteolytic induction effect and medical application thereof | 田边三菱制药株式会社 | 2024-05-10 | — | — | CN | disclosed |
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-3548033-B1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024028604-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024028603-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024028603-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024027706-A1 | BCL-XL DEGRADING COMPOUNDS | BEIJING NEOX BIOTECH LIMITED (CN) | 2024-02-08 | — | — | WO | disclosed |
| CN-112004816-B | PRC2 inhibitors | 米拉蒂医疗股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230363426-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11793220-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ENLIVEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ENLIVEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ENLIVEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| CN-116763791-A | Compounds and methods of use thereof | 普拉克西斯精密药物股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116731315-A | Boron-containing phthalonitrile resin and preparation method and application thereof | 中国科学院化学研究所 | 2023-09-12 | — | — | CN | disclosed |
| US-11737481-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| CN-116648453-A | 5-and 6-azaindole compounds for inhibiting Bcr-Abl tyrosine kinase | 活力疗法公司 | 2023-08-25 | — | — | CN | disclosed |
| EP-4225742-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | Enliven Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023139379-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) | REDX PHARMA PLC (GB) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139379-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) | REDX PHARMA PLC (GB) | 2023-07-27 | — | — | WO | disclosed |
| US-20230210790-A1 | GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES | THE JOHNS HOPKINS UNIVERSTY | 2023-07-06 | — | — | US | disclosed |
| CN-110337295-B | Compounds and methods of use thereof | 普拉克西斯精密药物股份有限公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-116157388-A | Carbocyclic amide derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20230139250-A1 | FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF | EYEPOINT PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230137025-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230137025-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-04-27 | — | — | US | disclosed |
| US-11629146-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-20230111917-A1 | KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| EP-4157998-A1 | GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES | The Johns Hopkins University (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-3421462-B1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-3421462-B1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2023-04-05 | — | — | EP | disclosed |
| WO-2023049724-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | ORIC PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| WO-2023034340-A1 | HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023034339-A1 | HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| US-20230065635-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-03-02 | — | — | US | disclosed |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
| WO-2022250104-A1 | QUINOLONE DERIVATIVE HAVING ANTIMALARIAL ACTIVITY | 国立大学法人長崎大学 | 2022-12-01 | — | — | WO | disclosed |
| US-11485738-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-11-01 | — | — | US | disclosed |
| US-20220264914-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-08-25 | — | — | US | disclosed |
| EP-4043466-A1 | PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| US-11413242-B2 | Formulations of Tie-2 activators and methods of use thereof | EyePoint Pharmaceuticals, Inc. (US) | 2022-08-16 | — | — | US | disclosed |
| WO-2022159439-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20220225647-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20220225646-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | disclosed |
| WO-2022109492-A1 | PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS | GOSSAMER BIOSERVICES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109492-A1 | PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS | GOSSAMER BIOSERVICES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-3746446-B1 | PRC2 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022076975-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076975-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022053000-A1 | CARBOCYCLIC AMIDE DERIVATIVE AND APPLICATION THEREOF IN MEDICINE | 四川海思科制药有限公司 | 2022-03-17 | — | — | WO | disclosed |
| US-11248170-B2 | Polymerizable compound and application thereof | JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) | 2022-02-15 | — | — | US | disclosed |
| EP-3344232-B1 | MICELLES FOR MUCOADHESIVE DRUG DELIVERY | UNIV MCMASTER (CA) | 2022-01-26 | — | — | EP | disclosed |
| US-11220509-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-01-11 | — | — | US | disclosed |
| EP-3740493-B1 | INHIBTEURS DE L'INDOLEAMINE 2,3-DIOXYGÉNASE ET/OU DU TRYPTOPHANE DIOXYGÉNASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-01 | — | — | EP | disclosed |
| US-20210300899-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210300899-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-09-16 | — | — | US | disclosed |
| US-11091495-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210230168-A1 | PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| US-11014909-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-11014909-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3819305-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-05-12 | — | — | EP | disclosed |
| CN-107709334-B | Novel amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2021-04-13 | — | — | CN | disclosed |
| US-20210101904-A1 | PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2021-04-08 | — | — | US | disclosed |
| CN-112543764-A | Amide compound with BET proteolysis induction effect and medical application thereof | 田边三菱制药株式会社 | 2021-03-23 | — | — | CN | disclosed |
| US-20210032252-A1 | PRC2 Inhibitors | Mirati Therapeutics, Inc. | 2021-02-04 | — | — | US | disclosed |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-31 | — | — | US | disclosed |
| US-20200397697-A1 | FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF | EyePoint Pharmaceuticals, Inc. | 2020-12-24 | — | — | US | disclosed |
| EP-3746446-A1 | PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3008056-B1 | NOVEL GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-12-09 | — | — | EP | disclosed |
| CN-112004816-A | PRC2 inhibitors | 米拉蒂医疗股份有限公司 | 2020-11-27 | — | — | CN | disclosed |
| EP-3740493-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | Idorsia Pharmaceuticals Ltd (CH) | 2020-11-25 | — | — | EP | disclosed |
| CN-105315319-B | Hepatitis C virus inhibitor and application thereof | 南京圣和药业股份有限公司 | 2020-11-20 | — | — | CN | disclosed |
| US-20200339883-A1 | POLYMERIZABLE COMPOUND AND APPLICATION THEREOF | JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) | 2020-10-29 | — | — | US | disclosed |
| US-20200283407-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200283407-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| EP-3423443-B1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | NOVARTIS AG (CH) | 2020-08-19 | — | — | EP | disclosed |
| US-10696658-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696658-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10662170-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-26 | — | — | US | disclosed |
| US-10611908-B2 | Micelles for mucoadhesive drug delivery | MCMASTER UNIVERSITY (CA) | 2020-04-07 | — | — | US | disclosed |
| US-10590079-B2 | Cyano-substituted indoles as LSD1 inhibitors | NOVARTIS AG (CH) | 2020-03-17 | — | — | US | disclosed |
| WO-2020009176-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | 田辺三菱製薬株式会社 | 2020-01-09 | — | — | WO | disclosed |
| US-10457687-B2 | Aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2019-10-29 | — | — | US | disclosed |
| EP-3548033-A1 | COMPOUNDS AND THEIR METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10421744-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-10421744-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2019-09-24 | — | — | US | disclosed |
| WO-2019152419-A1 | PRC2 INHIBITORS | MIRATI THERAPEUTICS, INC (US) | 2019-08-08 | — | — | WO | disclosed |
| EP-2551270-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES FOR USE AS PI3 KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2019-06-12 | — | — | EP | disclosed |
| EP-3476844-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | Emergent Product Development Gaithersburg Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10259823-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-04-16 | — | — | US | disclosed |
| US-20190105367-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2019-04-11 | — | — | US | disclosed |
| EP-3013813-B1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2019-04-03 | — | — | EP | disclosed |
| EP-3013813-B1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2019-04-03 | — | — | EP | disclosed |
| US-20190092724-A1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | NOVARTIS AG (CH) | 2019-03-28 | — | — | US | disclosed |
| US-10195178-B2 | GPR40 agonists in anti-diabetic drug combinations | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-05 | — | — | US | disclosed |
| US-20190031675-A1 | AMINOACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2019-01-31 | — | — | US | disclosed |
| EP-2925319-B1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIV ROCHESTER (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-3423443-A1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | Novartis AG (CH) | 2019-01-09 | — | — | EP | disclosed |
| US-20190002439-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190002439-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2019-01-03 | — | — | US | disclosed |
| EP-3421462-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | Pfizer Inc (US) | 2019-01-02 | — | — | EP | disclosed |
| EP-3421462-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | Pfizer Inc (US) | 2019-01-02 | — | — | EP | disclosed |
| US-10155021-B2 | Antimicrobial 4-oxoquinolizines | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2018-12-18 | — | — | US | disclosed |
| US-10131648-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-20 | — | — | US | disclosed |
| US-10106553-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-23 | — | — | US | disclosed |
| US-20180296555-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2018-10-18 | — | — | US | disclosed |
| US-10093655-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2018-10-09 | — | — | US | disclosed |
| EP-3313850-B1 | NEW AMINOACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2018-10-03 | — | — | EP | disclosed |
| US-20180265694-A1 | Micelles for Mucoadhesive Drug Delivery | MCMASTER UNIVERSITY (CA) | 2018-09-20 | — | — | US | disclosed |
| EP-2621491-B1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EMERGENT PRODUCT DEV GAITHERSBURG INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| EP-3344232-A1 | MICELLES FOR MUCOADHESIVE DRUG DELIVERY | Mcmaster University (CA) | 2018-07-11 | — | — | EP | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| EP-3313850-A1 | NEW AMINOACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Les Laboratoires Servier (FR) | 2018-05-02 | — | — | EP | disclosed |
| EP-3312176-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | Emergent Product Development Gaithersburg Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20180037571-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180037571-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180037571-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-9850232-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850232-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850232-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170362196-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-21 | — | — | US | disclosed |
| US-9822097-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822097-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822097-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-11-02 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| WO-2017180571-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017180457-A1 | GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | WO | disclosed |
| EP-3230276-A1 | GLP-1 RECEPTOR MODULATORS | Celgene International II Sarl (CH) | 2017-10-18 | — | — | EP | disclosed |
| EP-2917216-B1 | HETEROAROMATIC COMPOUNDS AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2917216-B1 | HETEROAROMATIC COMPOUNDS AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9790198-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-17 | — | — | US | disclosed |
| US-20170290800-A1 | GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-12 | — | — | US | disclosed |
| US-20170291908-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-12 | — | — | US | disclosed |
| EP-3080093-B1 | A NOVEL TRIAZOLO-PYRIDINE COMPOUND | LILLY CO ELI (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9745297-B2 | Compounds as modulators of RORC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-9745297-B2 | Compounds as modulators of RORC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-20170232060-A9 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2017-08-17 | — | — | US | disclosed |
| EP-3204361-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica N.V. (BE) | 2017-08-16 | — | — | EP | disclosed |
| US-20170209437-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2017-07-27 | — | — | US | disclosed |
| US-20170106045-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2017-04-20 | — | — | US | disclosed |
| EP-2457913-B1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARM LLC (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2090577-B1 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9598430-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-03-21 | — | — | US | disclosed |
| WO-2017035656-A1 | MICELLES FOR MUCOADHESIVE DRUG DELIVERY | MCMASTER UNIVERSITY (CA) | 2017-03-09 | — | — | WO | disclosed |
| US-20170057947-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057947-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057947-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2017-03-02 | — | — | US | disclosed |
| EP-3134404-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | Pfizer Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9540352-B2 | Substituted 1,7-naphthyridines as dopamine D1 ligands | PFIZER INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540352-B2 | Substituted 1,7-naphthyridines as dopamine D1 ligands | PFIZER INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540352-B2 | Substituted 1,7-naphthyridines as dopamine D1 ligands | PFIZER INC. (US) | 2017-01-10 | — | — | US | disclosed |
| WO-2016207226-A1 | NEW AMINOACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2016-12-29 | — | — | WO | disclosed |
| US-9527843-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527831-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527831-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527831-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527843-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527843-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-3080093-A1 | A NOVEL TRIAZOLO-PYRIDINE COMPOUND | ELI LILLY AND CO. (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2784065-B1 | GLYCINE REUPTAKE INHIBITOR AND USE THEREOF | BEIJING MEDISAN TECHNOLOGY CO LTD (CN) | 2016-10-05 | — | — | EP | disclosed |
| EP-2396322-B9 | 2-Morpholino-pyrido[3,2-d]pyrimidines | MERCK SERONO SA (CH) | 2016-09-14 | — | — | EP | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| US-9403818-B2 | Antimicrobial 4-oxoquinolizines | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160214993-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-07-28 | — | — | US | disclosed |
| US-20160200711-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200711-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200711-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2016-07-14 | — | — | US | disclosed |
| EP-3034078-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | Emergent Product Development Gaithersburg Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| WO-2016094729-A1 | GLP-1 RECEPTOR MODULATORS | CELGENE INTERNATIONAL II SARL (CH) | 2016-06-16 | — | — | WO | disclosed |
| US-20160159791-A1 | COMPOUNDS AS MODULATORS OF RORC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-09 | — | — | US | disclosed |
| US-20160159791-A1 | COMPOUNDS AS MODULATORS OF RORC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-09 | — | — | US | disclosed |
| EP-3013813-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | Pfizer Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-3008056-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | Receptos, Inc. (US) | 2016-04-20 | — | — | EP | disclosed |
| WO-2016057731-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-14 | — | — | WO | disclosed |
| US-20160102071-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-14 | — | — | US | disclosed |
| US-9260427-B2 | GLP-1 receptor modulators | RECEPTOS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2396322-B1 | 2-Morpholino-pyrido[3,2-d]pyrimidines | MERCK SERONO SA (CH) | 2016-02-03 | — | — | EP | disclosed |
| US-9242938-B2 | Glycine reuptake inhibitor and use thereof | BEIJING MEDISAN TECHNOLOGY CO., LTD (CN) | 2016-01-26 | — | — | US | disclosed |
| US-9242938-B2 | Glycine reuptake inhibitor and use thereof | BEIJING MEDISAN TECHNOLOGY CO., LTD (CN) | 2016-01-26 | — | — | US | disclosed |
| US-9242938-B2 | Glycine reuptake inhibitor and use thereof | BEIJING MEDISAN TECHNOLOGY CO., LTD (CN) | 2016-01-26 | — | — | US | disclosed |
| US-20150344474-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344474-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344474-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-12-03 | — | — | US | disclosed |
| WO-2015162516-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015162516-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| US-20150307494-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150307494-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150307494-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | disclosed |
| US-9139561-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139561-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139561-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2917216-A1 | HETEROAROMATIC COMPOUNDS AS DOPAMINE D1 LIGANDS | Pfizer Inc. (US) | 2015-09-16 | — | — | EP | disclosed |
| US-9133190-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133190-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133190-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9120793-B2 | Triazolo-pyridine compound | ELI LILLY AND COMPANY (US) | 2015-09-01 | — | — | US | disclosed |
| US-9107923-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9107923-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9107923-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2015-08-18 | — | — | US | disclosed |
| WO-2015106292-A1 | BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20150196561-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150196561-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150196561-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-07-16 | — | — | US | disclosed |
| WO-2015106292-A1 | BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20150175573-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175573-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175573-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-06-25 | — | — | US | disclosed |
| WO-2015088868-A1 | A NOVEL TRIAZOLO-PYRIDINE COMPOUND | ELI LILLY AND COMPANY (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20150166535-A1 | NOVELTRIAZOLO-PYRIDINE COMPOUND | ELI LILLY AND COMPANY | 2015-06-18 | — | — | US | disclosed |
| US-20150141435-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150133497-A1 | GLYCINE REUPTAKE INHIBITOR AND USE THEREOF | BEIJING MEDISAN TECHNOLOGY CO., LTD. (CN) | 2015-05-14 | — | — | US | disclosed |
| US-20150133497-A1 | GLYCINE REUPTAKE INHIBITOR AND USE THEREOF | BEIJING MEDISAN TECHNOLOGY CO., LTD. (CN) | 2015-05-14 | — | — | US | disclosed |
| US-20150133497-A1 | GLYCINE REUPTAKE INHIBITOR AND USE THEREOF | BEIJING MEDISAN TECHNOLOGY CO., LTD. (CN) | 2015-05-14 | — | — | US | disclosed |
| EP-2161273-B1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | LEUVEN K U RES & DEV (BE) | 2015-04-15 | — | — | EP | disclosed |
| US-8962842-B2 | 2-pyridone antimicrobial compositions | EVOLVA SA (CH) | 2015-02-24 | — | — | US | disclosed |
| WO-2015017335-A1 | AZAINDOLE COMPOUNDS AS MODULATORS OF RORC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-05 | — | — | WO | disclosed |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2015-01-08 | — | — | US | disclosed |
| US-20150005313-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005313-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005313-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2015-01-01 | — | — | US | disclosed |
| WO-2014207601-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014207601-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014201172-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20140336176-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336176-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336176-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2014-11-13 | — | — | US | disclosed |
| EP-2784065-A1 | GLYCINE REUPTAKE INHIBITOR AND USE THEREOF | Beijing Medisan Technology Co. Ltd. (CN) | 2014-10-01 | — | — | EP | disclosed |
| US-8822494-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822494-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822494-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2014-09-02 | — | — | US | disclosed |
| WO-2014072882-A1 | HETEROAROMATIC COMPOUNDS AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2014-05-15 | — | — | WO | disclosed |
| WO-2014072882-A1 | HETEROAROMATIC COMPOUNDS AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20140128374-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128374-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128374-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC (US) | 2014-05-08 | — | — | US | disclosed |
| US-8642604-B2 | Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-04 | — | — | US | disclosed |
| US-8609666-B2 | 2-morpholino-pyrido[3,2-D]pyrimidines | MERCK SERONO SA (CH) | 2013-12-17 | — | — | US | disclosed |
| EP-2670410-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | Evolva SA (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-20130252882-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EVOLVA SA (CH) | 2013-09-26 | — | — | US | disclosed |
| US-20130245035-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2013-09-19 | — | — | US | disclosed |
| EP-2621491-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | Evolva SA (CH) | 2013-08-07 | — | — | EP | disclosed |
| EP-2004654-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES FOR USE AS KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8372976-B2 | Methods of treatment comprising the administration of heteroaryl compounds | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2551270-A2 | PYRAZOLOPYRMIDINE DERIVATIVES FOR USE AS PI3 KINASE ANTAGONISTS | The Regents of The University of California (US) | 2013-01-30 | — | — | EP | disclosed |
| EP-2546254-A1 | Imidazo[4,5-C]pyridine compounds and methods of antiviral treatment | K.U.Leuven Research & Development (BE) | 2013-01-16 | — | — | EP | disclosed |
| US-8329727-B2 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329727-B2 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| WO-2012104305-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EVOLVA SA (CH) | 2012-08-09 | — | — | WO | disclosed |
| EP-2457913-A2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | Signal Pharmaceuticals LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| WO-2012047487-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | EVOLVA SA (CH) | 2012-04-12 | — | — | WO | disclosed |
| EP-2078016-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-2396322-A1 | 2-MORPHOLINO-PYRIDOÝ3,2-D¨PYRIMIDINES | Merck Serono SA (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-20110301144-A1 | Kinase Antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110293564-A1 | 2-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2011-12-01 | — | — | US | disclosed |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-06 | — | — | US | disclosed |
| US-7981893-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-7960552-B2 | 6-[4-({[3-(2,6-Dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-2-quinolinecarboxylic acid and the potassium salt; antidiabetic agents; improved glucose tolerance and decreased insulin resistance | GLAXOSMITHKLINE LLC (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960552-B2 | 6-[4-({[3-(2,6-Dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-2-quinolinecarboxylic acid and the potassium salt; antidiabetic agents; improved glucose tolerance and decreased insulin resistance | GLAXOSMITHKLINE LLC (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960552-B2 | 6-[4-({[3-(2,6-Dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-2-quinolinecarboxylic acid and the potassium salt; antidiabetic agents; improved glucose tolerance and decreased insulin resistance | GLAXOSMITHKLINE LLC (US) | 2011-06-14 | — | — | US | disclosed |
| US-7790730-B2 | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation | GILEAD SCIENCES, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| WO-2010091996-A1 | 2-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2010-08-19 | — | — | WO | disclosed |
| US-7737152-B2 | 6-carboaryl-oxy-pyrazin-2-yl-carboaryl-amines and compositions comprising said compounds | THE WELLCOME TRUST LIMITED (GB) | 2010-06-15 | — | — | US | disclosed |
| US-20100120775-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120775-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120775-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2161273-A1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | K.U.Leuven Research & Development (BE) | 2010-03-10 | — | — | EP | disclosed |
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-02-04 | — | — | US | disclosed |
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-02-04 | — | — | US | disclosed |
| US-7648998-B2 | 5-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine; hepatitis-C-virus | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2010-01-19 | — | — | US | disclosed |
| US-7648998-B2 | 5-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine; hepatitis-C-virus | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2010-01-19 | — | — | US | disclosed |
| US-20100009963-A1 | KINASE ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-01-14 | — | — | US | disclosed |
| EP-2108642-A1 | JAK INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-10-14 | — | — | EP | disclosed |
| US-7585868-B2 | Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-09-08 | — | — | US | disclosed |
| US-20090208456-A1 | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation | GILEAD SCIENCES, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| EP-2090577-A2 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | Signal Pharmaceuticals LLC (US) | 2009-08-19 | — | — | EP | disclosed |
| US-7566708-B2 | Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566708-B2 | Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566708-B2 | Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-28 | — | — | US | disclosed |
| EP-2079307-A2 | FARNESOID X RECEPTOR AGONISTS | SmithKline Beecham Corporation (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-2078016-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-01-22 | — | — | US | disclosed |
| EP-2004654-A2 | KINASE ANTAGONISTS | The Regents of the University of California (US) | 2008-12-24 | — | — | EP | disclosed |
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | disclosed |
| EP-1919470-A1 | FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051942-A2 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051942-A2 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080015191-A1 | Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds | THE WELLCOME TRUST LIMITED (UK) | 2008-01-17 | — | — | US | disclosed |
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| WO-2007114926-A2 | KINASE ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-10-11 | — | — | WO | disclosed |
| EP-1831184-A2 | PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS | The Wellcome Trust Limited (GB) | 2007-09-12 | — | — | EP | disclosed |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-08-30 | — | — | US | disclosed |
| WO-2007023105-A1 | FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | WO | disclosed |
| EP-1706403-A2 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | K.U.Leuven Research & Development (BE) | 2006-10-04 | — | — | EP | disclosed |
| WO-2006067466-A2 | PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS | THE WELLCOME TRUST LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| US-20050222198-A1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | K.U. LEUVEN RESEARCH & DEVELOPMENT, GERHARD PUERSTINGER AND GILEAD SCIENCES, INC. | 2005-10-06 | — | — | US | disclosed |
| US-20050203091-A1 | Heteroaryl-fused pyrazolo derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-15 | — | — | US | disclosed |
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005063744-A2 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005063744-A2 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | ALOX15 4319/4885CYP3A4 3621/4885CHRM1 90/4885 |
| US-20100120775-A1 | Farnesoid X Receptor Agonists | NR1H4, NR1H3, NR1H2 | ALOX15 813/4885CYP3A4 110/4885CHRM1 538/4885 |
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | MTOR, PI4KA, PIK3CA | ALOX15 2761/4885CYP3A4 2041/4885CHRM1 4838/4885 |
| US-20150133497-A1 | GLYCINE REUPTAKE INHIBITOR AND USE THEREOF | SLC6A2, SLC6A5, SLC6A4 | ALOX15 936/4885CYP3A4 430/4885CHRM1 139/4885 |
| US-10590079-B2 | Cyano-substituted indoles as LSD1 inhibitors | KDM1A, KDM1B, KDM3A | ALOX15 2683/4885CYP3A4 1490/4885CHRM1 298/4885 |
| US-20150344474-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD1, DRD2, DRD3 | ALOX15 859/4885CYP3A4 1226/4885CHRM1 38/4885 |
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | ALOX15 4319/4885CYP3A4 3621/4885CHRM1 90/4885 |
| US-20190105367-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | ALOX15 1270/4885CYP3A4 55/4885CHRM1 3705/4885 |
| US-20260042745-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | PTGER4, PTGER1, PTGER2 | ALOX15 252/4885CYP3A4 350/4885CHRM1 153/4885 |
| US-20170290800-A1 | GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS | GPR119, GLP1R, GPR65 | ALOX15 2155/4885CYP3A4 1085/4885CHRM1 662/4885 |
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | HTR6, HTR3C, OPRD1 | ALOX15 470/4885CYP3A4 1065/4885CHRM1 87/4885 |
| US-10155021-B2 | Antimicrobial 4-oxoquinolizines | DCAF15, CUL4A, CUL4B | ALOX15 1283/4885CYP3A4 50/4885CHRM1 3676/4885 |
| US-11629146-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity | SCN1A, SCN5A, SCN3A | ALOX15 3065/4885CYP3A4 2826/4885CHRM1 3191/4885 |
| US-11091495-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | ALOX15 3812/4885CYP3A4 2921/4885CHRM1 4818/4885 |
| US-20170291908-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR52 | ALOX15 1381/4885CYP3A4 2282/4885CHRM1 345/4885 |
| US-10195178-B2 | GPR40 agonists in anti-diabetic drug combinations | GPR119, GLP1R, GPR65 | ALOX15 2155/4885CYP3A4 1085/4885CHRM1 662/4885 |
| US-20180296555-A1 | 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS | TOP2A, TOP1, TOP2B | ALOX15 2870/4885CYP3A4 1545/4885CHRM1 2741/4885 |
| US-20160214993-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | ALOX15 4319/4885CYP3A4 3621/4885CHRM1 90/4885 |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | ALOX15 4450/4885CYP3A4 2412/4885CHRM1 4723/4885 |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ABL1, ABL2, BCR | ALOX15 3664/4885CYP3A4 3060/4885CHRM1 4501/4885 |
| US-20150196561-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | SNCA, DRD1, DRD2 | ALOX15 1585/4885CYP3A4 501/4885CHRM1 8/4885 |
| US-20110293564-A1 | 2-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | PIK3CA, PIK3CD, PIK3CB | ALOX15 746/4885CYP3A4 3939/4885CHRM1 4611/4885 |
| US-20170362196-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR52, GPR65 | ALOX15 1494/4885CYP3A4 1434/4885CHRM1 414/4885 |
| US-11485738-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | ALOX15 4083/4885CYP3A4 3439/4885CHRM1 4839/4885 |
| US-11413242-B2 | Formulations of Tie-2 activators and methods of use thereof | TIE1, TEK, KDR | ALOX15 2711/4885CYP3A4 4472/4885CHRM1 4277/4885 |
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | MLKL, MARCKS, MAP3K4 | ALOX15 4244/4885CYP3A4 2342/4885CHRM1 4191/4885 |
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | DRD2, DRD1, HTR1D | ALOX15 484/4885CYP3A4 952/4885CHRM1 136/4885 |
| US-10421744-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | DRD1, SNCA, DRD2 | ALOX15 1285/4885CYP3A4 362/4885CHRM1 9/4885 |
| US-20160159791-A1 | COMPOUNDS AS MODULATORS OF RORC | RORC, RORB, RORA | ALOX15 1557/4885CYP3A4 374/4885CHRM1 1084/4885 |
| US-20230111917-A1 | KINASE ANTAGONISTS | MTOR, RPS6KA3, AKT3 | ALOX15 4758/4885CYP3A4 3979/4885CHRM1 4850/4885 |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | JAK2, GLS2, NFKBIA | ALOX15 632/4885CYP3A4 1201/4885CHRM1 4074/4885 |
| US-20100009963-A1 | KINASE ANTAGONISTS | MTOR, RPS6KA3, AKT3 | ALOX15 4758/4885CYP3A4 3979/4885CHRM1 4850/4885 |
| US-20250236621-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | ALOX15 3664/4885CYP3A4 3060/4885CHRM1 4501/4885 |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | ALOX15 3664/4885CYP3A4 3060/4885CHRM1 4501/4885 |
| US-20210300899-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, HTR1D | ALOX15 484/4885CYP3A4 952/4885CHRM1 136/4885 |
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | ALOX15 2668/4885CYP3A4 2930/4885CHRM1 2467/4885 |
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | CYP3A5, TPMT, ZC3HAV1 | ALOX15 3769/4885CYP3A4 10/4885CHRM1 2621/4885 |
| US-20170106045-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | ALOX15 1270/4885CYP3A4 55/4885CHRM1 3705/4885 |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | ZC3HAV1, TPMT, DPP4 | ALOX15 3449/4885CYP3A4 13/4885CHRM1 2247/4885 |
| US-20190002439-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD1, SNCA, DRD2 | ALOX15 1285/4885CYP3A4 362/4885CHRM1 9/4885 |
| US-20080015191-A1 | Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds | BRAF, RAF1, BCOR | ALOX15 2154/4885CYP3A4 2010/4885CHRM1 3152/4885 |
| US-20240317713-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, HTR1D | ALOX15 484/4885CYP3A4 952/4885CHRM1 136/4885 |
| US-20170232060-A9 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | ALOX15 1270/4885CYP3A4 55/4885CHRM1 3705/4885 |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ABL1, ABL2, BCR | ALOX15 3664/4885CYP3A4 3060/4885CHRM1 4501/4885 |
| US-20140336176-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD1, DRD2, DRD3 | ALOX15 859/4885CYP3A4 1226/4885CHRM1 38/4885 |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | ALOX15 2668/4885CYP3A4 2930/4885CHRM1 2467/4885 |
| US-20200397697-A1 | FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF | TIE1, TEK, KDR | ALOX15 2711/4885CYP3A4 4472/4885CHRM1 4277/4885 |
| US-20140128374-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD1, DRD2, DRD3 | ALOX15 859/4885CYP3A4 1226/4885CHRM1 38/4885 |
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | ALOX15 1656/4885CYP3A4 64/4885CHRM1 318/4885 |
| US-20190031675-A1 | AMINOACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BAX, ARG2, ANXA5 | ALOX15 1524/4885CYP3A4 1444/4885CHRM1 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.